Cefprozil: profile and news

Par Pharmaceutical Reports Sales and Earnings for 2005 Feb 28, 2006
...generic version of Adoxa(R) licensed from Bradley Pharmaceuticals, Inc.; and - Par received final FDA approval and began shipping cefprozil tablets, cefprozil ... - MSN Money

Lupin hunts for brand buyouts in US, Europe Feb 3, 2006
The company launched five products in the US market in the last quarter, which included Cefprozil suspension and tablets on patent expiry. - Daily News & Analysis,

Orchid receives USFDA nod for Cefprozil tablets Jan 24, 2006
...based pharma major, Orchid Chemicals & Pharmaceuticals announced that it has received the formal approval from the USFDA for its ANDA for Cefprozil tablets USP ... - Express Pharma Pulse,

Third-quarter earnings perk up Lupin by 5% Jan 30, 2006
...investment of Rs 26 crore. Lupin launched five products in the US market in the quarter, which included Cefprozil suspension and tablets. - Business Standard,

First-Time Generic Approvals: Zithromax, Cefzil, Zonegran Jan 27, 2006
...the treatment of community-acquired pneumonia and for pelvic inflammatory disease caused by susceptible strains of designated microorganisms; cefprozil 125-mg/5 ... - Medscape (subscription)

Orchid Q3 turnover up Jan 19, 2006
The growth momentum of the second quarter (Q2) has been sustained with the ramp-up of Ceftriaxone injection and introduction of Cefprozil tablets and ... - Webindia123,

for Oral Suspension Jan 18, 2006
...recently announced that it had received final approval from the FDA for its Abbreviated New Drug Application for cefprozil for oral suspension. ... - Pharmaceutical Processing,

Orchid gets USFDA nod for Cefoxitin Jan 27, 2006
Director K Raghavendra Rao. The current US market size for Cefprozil tablets is estimated at 117 million dollars. This is the eighth ... - NewKerala.com,

Zacks.com Announces That Vivian Lewis Highlights the Following ... Jan 17, 2006
C virus. It also won FDA ok for cefprozil in tablet and oral form, and oxydine in 3 doses including extended release. Successful ... - Business Wire (press release),

FDA approves Teva antibiotic Cefprozil 11 Dec 2005
...has announced that the US Food and Drug Administration has granted approval for the its ANDAs (abbreviated new drug applications) for Cefprozil Tablets USP ... - Globes,

Real growth will happen from 2007: Orchid Dec 10, 2005
Two more are to be introduced shortly, once the approvals are got - Cefprozil, whose patent expires on December 23 and Cefoxitin, patent of which has expired. ... - Sify,

Dongkuk Steel, Hon Hai, Hyundai: Asia Ex-Japan Equity Preview Dec 9, 2005
Co.'s antibiotic Cefzil in the US Lupin won approval from the Food and Drug Administration to sell 250- and 500-milligram tablets of cefprozil, the company ... - Bloomberg

Orchid to unveil 2 more antibiotics in US Aug 17, 2005
130 crore) this year. Cefprozil, a cephalosporin, is to lose its patent protection in the US in December 2005. Orchid expects to ... - Sify,

Orchid Chemicals to launch two more antibiotics in US Aug 17, 2005
...according to sources. Cefprozil, a cephalosporin, is to lose its patent protection in the US in December 2005. Orchid expects to ... - Myiris.com,

Orchid announces 1:2 bonus Jul 18, 2005
Speaking on the marketing plans, Narayanan said Orchid's two premium products Ceftraixone and Cefprozil, which will become off patent this fiscal, has a ... - Newindpress

USFDA inspects Orchid Pharma Mar 7, 2005
The ANDAs reviewed in the inspection include blockbuster products such as Ceftriaxone injectabte and Cefprozil oral dosage forms, going off-patent in July 2005 ... - Economic Times,

Other information

Indication
For the treatment of the following infections (respiratory, skin, soft tissue, UTI, ENT) caused by; S. pneumoniae, H. influenzae, staphylococci, S. pyogenes (group A beta-hemolytic streptococci), E. coli, P. mirabilis, Klebsiella sp, coagulase-negative staph

Pharmacology
Cefprozil, a semisynthetic, second-generation cephalosporin, is used to treat otitis media, soft-tissue infections, and respiratory tract infections.

Mechanism Of Action
Cefprozil, like the penicillins, is a beta-lactam antibiotic. By binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, it inhibits the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins; it is possible that cefprozil interferes with an autolysin inhibitor.

Drug Category
Anti-bacterial Agents; Cephalosporins; ATC:J01DC10

Brand Names/Synonyms
Arzimol; Brisoral; Cefprozil anhydrous; Cefprozilo [INN-Spanish]; Cefprozilum [INN-Latin]; Cefzil; Cronocef; Procef; Serozil

Dosage Forms
Cefzil tablets contain cefprozil equivalent to 250 mg or 500 mg of anhydrous cefprozil.

Absorption
Oral_~95%

Interactions
Nephrotoxicity has been reported following concomitant administration of aminoglycoside antibiotics and cephalosporin antibiotics. Concomitant administration of probenecid doubled the AUC for cefprozil. The bioavailability of the capsule formulation of cefprozil was not affected when administered 5 minutes following an antacid.

Chemical IUPAC Name
8-[2-amino-2-(4-hydroxyphenyl)-acetyl]amino-7-oxo-4-prop-1-enyl-2-thia-6-azabicyclo[4.2.0]oct-4-ene-5-carboxylicacid

Chemical Formula
C18H19N3O5S

Half Life
1.3 hours

Drug Type
Approved Drug

# Accession No
APRD00461

CAS Registry Number
92665-29-7